Guidance Developed for Addressing Use of Nonstatin Therapies

MONDAY, Aug. 29, 2022 -- Several new nonstatin agents have low-density lipoprotein cholesterol-lowering efficacy and can be considered for patients at risk for atherosclerotic cardiovascular disease (ASCVD), according to an expert consensus decision...